Stockscreener 앱 받기
1.36
0.01%
-0.000100
시간 외 거래:
1.43
0.07
+5.15%
전일 마감가:
$1.3601
열려 있는:
$1.45
하루 거래량:
19,367
Relative Volume:
0.36
시가총액:
$7.90M
수익:
-
순이익/손실:
$-13.32M
주가수익비율:
-0.2259
EPS:
-6.02
순현금흐름:
$-13.01M
1주 성능:
+0.74%
1개월 성능:
+4.62%
6개월 성능:
-24.44%
1년 성능:
-15.00%
1일 변동 폭
$1.33
$1.45
1주일 범위
$1.2894
$1.45
52주 변동 폭
$1.145
$2.78
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve
Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT
Plus Therapeutics reports progress in brain cancer trial - Investing.com
Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian
Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga
The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - The New York Times
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers
Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance
Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World
Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada
From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech
Plus Therapeutics to present at CNS Annual Meeting - Investing.com
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan
Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences
Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada
Plus Therapeutics director buys $6k worth of shares - Investing.com
Plus Therapeutics director acquires $8.5k in stock - Investing.com
Plus Therapeutics director acquires $8.5k in stock By Investing.com - Investing.com Canada
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer - Yahoo Finance
Plus Therapeutics director buys $6.7k in company stock - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com Australia
Elevar Therapeutics Reports Advances in HCC and Other - GlobeNewswire
Plus Therapeutics CEO buys $9.8k in company stock - Investing.com
With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights - STAT
Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial - STAT
Plus Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Plus Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Zenas, Bicara set out to raise $180M-plus in separate IPOs to fund autoimmune, cancer prospects - Fierce Biotech
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $20.00 at Ascendiant Capital Markets - Defense World
Plus Therapeutics stock sees reduced target after softer-than-expected Q2 results - Investing.com
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):